Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
Public ClinicalTrials.gov record NCT05456685. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRα Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.
Study identification
- NCT ID
- NCT05456685
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 125 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2022 (Actual)
- Primary completion
- Nov 2026 (Estimated)
- Completion
- Nov 2026 (Estimated)
- Last update posted
- Oct 28, 2025
2022 – 2026
United States locations
- U.S. sites
- 35
- U.S. states
- 20
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center /ID# 268906 | Tucson | Arizona | 85704 | — |
| Women'S Cancer Research Network - Cogi /ID# 268912 | Fresno | California | 93710 | — |
| Providence - St. Jude Medical /ID# 268911 | Fullerton | California | 92835-3826 | — |
| Moores Cancer Center /ID# 268888 | La Jolla | California | 92037 | — |
| USC Norris Comprehensive Cancer Center /ID# 268964 | Los Angeles | California | 90033 | — |
| University of California Los Angeles Medical Center /ID# 268883 | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian /ID# 268907 | Newport Beach | California | 92663 | — |
| UC Davis Comprehensive Cancer Center /ID# 269085 | Sacramento | California | 95817 | — |
| Scripps Md Anderson - Prebys Cancer Center /ID# 268966 | San Diego | California | 92103 | — |
| California Pacific Medical Center - Van Ness Campus /ID# 268886 | San Francisco | California | 94109 | — |
| Smilow Cancer Hospital at Yale New Haven /ID# 268889 | New Haven | Connecticut | 06519-1110 | — |
| AdventHealth Orlando /ID# 268920 | Orlando | Florida | 32803 | — |
| Sarasota Memorial Hospital /ID# 268882 | Sarasota | Florida | 34239 | — |
| Moffitt Cancer Center /ID# 269089 | Tampa | Florida | 33612 | — |
| Winship Cancer Institute of Emory University /ID# 268913 | Atlanta | Georgia | 30322 | — |
| Northwestern University- Robert H. Lurie Comprehensive Cancer Center /ID# 268957 | Chicago | Illinois | 60610 | — |
| Women'S Cancer Care /ID# 268898 | Covington | Louisiana | 70433 | — |
| Massachusetts General Hospital /ID# 268879 | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute /ID# 268881 | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute - Detroit /ID# 268890 | Detroit | Michigan | 48201 | — |
| Washington University School of Medicine - St. Louis /ID# 268897 | St Louis | Missouri | 63130 | — |
| The Center Of Hope /ID# 268884 | Reno | Nevada | 89511 | — |
| Md Anderson Cancer Center At Cooper /ID# 268885 | Camden | New Jersey | 08103 | — |
| Holy Name Medical Center /ID# 268903 | Teaneck | New Jersey | 07666 | — |
| University of New Mexico Comprehensive Cancer Center /ID# 268961 | Albuquerque | New Mexico | 87102 | — |
| Presbyterian Rust Medical Center /ID# 278582 | Rio Rancho | New Mexico | 87124 | — |
| Long Island Jewish Medical Center /ID# 268909 | New Hyde Park | New York | 11040 | — |
| Columbia University Irving Medical Center /ID# 268887 | New York | New York | 10032 | — |
| University of North Carolina Medical Center /ID# 268963 | Chapel Hill | North Carolina | 27514 | — |
| Duke Cancer Center Macon Pond /ID# 268910 | Raleigh | North Carolina | 27607 | — |
| OU Health - Stephenson Cancer Center /ID# 268878 | Oklahoma City | Oklahoma | 73104 | — |
| Women & Infants Hospital /ID# 268895 | Providence | Rhode Island | 02905 | — |
| MUSC Hollings Cancer Center /ID# 268892 | Charleston | South Carolina | 29425 | — |
| University of Texas - Southwestern Medical Center /ID# 268891 | Dallas | Texas | 75235 | — |
| Duplicate_Kadlec Clinic Heme-Onc /ID# 268580 | Kennewick | Washington | 99336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05456685, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2025 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05456685 live on ClinicalTrials.gov.